{"pmid":32391184,"pmcid":"PMC7202269","title":"Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease.","text":["Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease.","Coronavirus 3C-like protease (3CL(Pro)) is a highly conserved cysteine protease employing a catalytic dyad for its functions. 3CL(Pro) is essential to the viral life cycle and, therefore, is an attractive target for developing antiviral agents. However, the detailed catalytic mechanism of coronavirus 3CL(Pro) remains largely unknown. We took an integrated approach of employing X-ray crystallography, mutational studies, enzyme kinetics study, and inhibitors to gain insights into the mechanism. Such experimental work is supplemented by computational studies, including the prereaction state analysis, the ab initio calculation of the critical catalytic step, and the molecular dynamic simulation of the wild-type and mutant enzymes. Taken together, such studies allowed us to identify a residue pair (Glu-His) and a conserved His as critical for binding; a conserved GSCGS motif as important for the start of catalysis, a partial negative charge cluster (PNCC) formed by Arg-Tyr-Asp as essential for catalysis, and a conserved water molecule mediating the remote interaction between PNCC and catalytic dyad. The data collected and our insights into the detailed mechanism have allowed us to achieve a good understanding of the difference in catalytic efficiency between 3CL(Pro) from SARS and MERS, conduct mutational studies to improve the catalytic activity by 8-fold, optimize existing inhibitors to improve the potency by 4-fold, and identify a potential allosteric site for inhibitor design. All such results reinforce each other to support the overall catalytic mechanism proposed herein.","ACS Catal","Wang, Hao","He, Shuai","Deng, Weilong","Zhang, Ying","Li, Guobang","Sun, Jixue","Zhao, Wei","Guo, Yu","Yin, Zheng","Li, Dongmei","Shang, Luqing","32391184"],"abstract":["Coronavirus 3C-like protease (3CL(Pro)) is a highly conserved cysteine protease employing a catalytic dyad for its functions. 3CL(Pro) is essential to the viral life cycle and, therefore, is an attractive target for developing antiviral agents. However, the detailed catalytic mechanism of coronavirus 3CL(Pro) remains largely unknown. We took an integrated approach of employing X-ray crystallography, mutational studies, enzyme kinetics study, and inhibitors to gain insights into the mechanism. Such experimental work is supplemented by computational studies, including the prereaction state analysis, the ab initio calculation of the critical catalytic step, and the molecular dynamic simulation of the wild-type and mutant enzymes. Taken together, such studies allowed us to identify a residue pair (Glu-His) and a conserved His as critical for binding; a conserved GSCGS motif as important for the start of catalysis, a partial negative charge cluster (PNCC) formed by Arg-Tyr-Asp as essential for catalysis, and a conserved water molecule mediating the remote interaction between PNCC and catalytic dyad. The data collected and our insights into the detailed mechanism have allowed us to achieve a good understanding of the difference in catalytic efficiency between 3CL(Pro) from SARS and MERS, conduct mutational studies to improve the catalytic activity by 8-fold, optimize existing inhibitors to improve the potency by 4-fold, and identify a potential allosteric site for inhibitor design. All such results reinforce each other to support the overall catalytic mechanism proposed herein."],"journal":"ACS Catal","authors":["Wang, Hao","He, Shuai","Deng, Weilong","Zhang, Ying","Li, Guobang","Sun, Jixue","Zhao, Wei","Guo, Yu","Yin, Zheng","Li, Dongmei","Shang, Luqing"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391184","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1021/acscatal.0c00110","locations":["PNCC"],"e_drugs":["Glutamic Acid","Water","arginyl-tyrosyl-aspartic acid","Histidine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666528580260069376,"score":9.490897,"similar":[{"pmid":32194944,"pmcid":"PMC7062204.2","title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","text":["Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.","F1000Res","Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin","32194944"],"abstract":["We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes."],"journal":"F1000Res","authors":["Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32194944","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.12688/f1000research.22457.2","keywords":["2019-ncov","3c-like protease","covid-19","hcv","hepatitis c virus","sars","antiviral","coronavirus","drug repurpose","ledipasvir","molecular modelling","velpatasvir","virtual screening"],"e_drugs":["velpatasvir","ledipasvir, sofosbuvir drug combination","ledipasvir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490055688192,"score":451.95126},{"pmid":32402186,"title":"Targeting the dimerization of main protease of coronaviruses: A potential broad-spectrum therapeutic strategy.","text":["Targeting the dimerization of main protease of coronaviruses: A potential broad-spectrum therapeutic strategy.","A new coronavirus (CoV) caused a pandemic COVID-19, which has become a global health care emergency in the present date. The virus has been termed as SARS-CoV-2 (Severe Acute Respiratory Syndrome-Cororavirus-2) and has a genome similar (~82%) to the SARS-CoV (SARS coronavirus). An attractive therapeutic target for CoVs is the M(pro) (main protease) or 3CL(pro) (3-chymotrypsin-like cysteine protease) as the enzyme plays a key role in the polyprotein processing and is active in a dimeric form. Further, M(pro) is highly conserved among various CoVs as the mutation in M(pro) is often lethal to the virus. Thus, drugs targeting M(pro) enzyme significantly reduce the risk of mutation-mediated drug resistance and display broad-spectrum antiviral activity. The combinatorial design of peptide-based inhibitors targeting the dimerization of SARS-CoV M(pro) represent a potential therapeutic strategy. In this regard, we compiled the literature reports highlighting the effect of mutations and N-terminal deletion of residues of SARS-CoV M(pro) on its dimerization and thus, catalytic activity. We believe that the present review will stimulate research in this less explored, yet quite significant area. The effect of the COVID-19 epidemic and the possibility of future CoV outbreaks strongly emphasize the urgent need for the design and development of potent antiviral agents against CoV infections.","ACS Comb Sci","Goyal, Bhupesh","Goyal, Deepti","32402186"],"abstract":["A new coronavirus (CoV) caused a pandemic COVID-19, which has become a global health care emergency in the present date. The virus has been termed as SARS-CoV-2 (Severe Acute Respiratory Syndrome-Cororavirus-2) and has a genome similar (~82%) to the SARS-CoV (SARS coronavirus). An attractive therapeutic target for CoVs is the M(pro) (main protease) or 3CL(pro) (3-chymotrypsin-like cysteine protease) as the enzyme plays a key role in the polyprotein processing and is active in a dimeric form. Further, M(pro) is highly conserved among various CoVs as the mutation in M(pro) is often lethal to the virus. Thus, drugs targeting M(pro) enzyme significantly reduce the risk of mutation-mediated drug resistance and display broad-spectrum antiviral activity. The combinatorial design of peptide-based inhibitors targeting the dimerization of SARS-CoV M(pro) represent a potential therapeutic strategy. In this regard, we compiled the literature reports highlighting the effect of mutations and N-terminal deletion of residues of SARS-CoV M(pro) on its dimerization and thus, catalytic activity. We believe that the present review will stimulate research in this less explored, yet quite significant area. The effect of the COVID-19 epidemic and the possibility of future CoV outbreaks strongly emphasize the urgent need for the design and development of potent antiviral agents against CoV infections."],"journal":"ACS Comb Sci","authors":["Goyal, Bhupesh","Goyal, Deepti"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402186","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1021/acscombsci.0c00058","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494701666304,"score":389.72696},{"pmid":32367767,"title":"Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.","text":["Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.","The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic.","J Biomol Struct Dyn","Gyebi, Gideon A","Ogunro, Olalekan B","Adegunloye, Adegbenro P","Ogunyemi, Oludare M","Afolabi, Saheed O","32367767"],"abstract":["The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic."],"journal":"J Biomol Struct Dyn","authors":["Gyebi, Gideon A","Ogunro, Olalekan B","Adegunloye, Adegbenro P","Ogunyemi, Oludare M","Afolabi, Saheed O"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367767","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1764868","keywords":["covid-19","coronavirus 3clpro","molecular docking","natural product","sars-cov-2"],"locations":["Cryptoquindoline","Cryptospirolepine","Isoiguesterin"],"e_drugs":["10'-hydroxyusambarensine","Lopinavir","Ritonavir","Alkaloids","iguesterin","cryptospirolepine","20-epibryonolic acid","Terpenes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496156303362,"score":378.13483},{"pmid":32293875,"pmcid":"PMC7184878","title":"Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.","text":["Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.","Since the emergence of a novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China, neither a specific vaccine nor an antiviral drug against SARS-CoV-2 has become available. However, a combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations, and pair interaction energy analyses based on MM/PB(GB)SA and FMO-MP2/PCM/6-31G* methods. Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CL(pro). Ritonavir showed a somewhat higher number atomic contacts, a somewhat higher binding efficiency, and a somewhat higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via the formation of two hydrogen bonds. The interactions in terms of electrostatics, dispersion, and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.","Biochemistry","Nutho, Bodee","Mahalapbutr, Panupong","Hengphasatporn, Kowit","Pattaranggoon, Nawanwat Chainuwong","Simanon, Nattapon","Shigeta, Yasuteru","Hannongbua, Supot","Rungrotmongkol, Thanyada","32293875"],"abstract":["Since the emergence of a novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China, neither a specific vaccine nor an antiviral drug against SARS-CoV-2 has become available. However, a combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations, and pair interaction energy analyses based on MM/PB(GB)SA and FMO-MP2/PCM/6-31G* methods. Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CL(pro). Ritonavir showed a somewhat higher number atomic contacts, a somewhat higher binding efficiency, and a somewhat higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via the formation of two hydrogen bonds. The interactions in terms of electrostatics, dispersion, and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19."],"journal":"Biochemistry","authors":["Nutho, Bodee","Mahalapbutr, Panupong","Hengphasatporn, Kowit","Pattaranggoon, Nawanwat Chainuwong","Simanon, Nattapon","Shigeta, Yasuteru","Hannongbua, Supot","Rungrotmongkol, Thanyada"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293875","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acs.biochem.0c00160","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ritonavir","Lopinavir","4-(3-benzyl-4-(5-(2-fluorophenyl)-ruan-2-ylmethylene)-5-oxo-4,5-dihydropyrazol-1-yl)benzoic acid","Water"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494353801221,"score":342.8949},{"pmid":32396767,"title":"Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.","text":["Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.","The recent outbreak of novel \"coronavirus disease 2019\" (COVID-19) has spread rapidly worldwide, causing a global pandemic. In the present work, we have elucidated the mechanism of binding of two inhibitors, namely alpha-ketoamide and Z31792168, to SARS-CoV-2 main protease (M(pro) or 3CL(pro)) by using all-atom molecular dynamics simulations and free energy calculations. We calculated the total binding free energy (DeltaGbind) of both inhibitors and further decomposed DeltaGbind into various forces governing the complex formation using the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method. Our calculations reveal that alpha-ketoamide is more potent (DeltaGbind= - 9.05 kcal/mol) compared to Z31792168 (DeltaGbind= - 3.25 kcal/mol) against COVID-19 3CL(pro). The increase in DeltaGbind for alpha-ketoamide relative to Z31792168 arises due to an increase in the favorable electrostatic and van der Waals interactions between the inhibitor and 3CL(pro). Further, we have identified important residues controlling the 3CL(pro)-ligand binding from per-residue based decomposition of the binding free energy. Finally, we have compared DeltaGbind of these two inhibitors with the anti-HIV retroviral drugs, such as lopinavir and darunavir. It is observed that alpha-ketoamide is more potent compared to lopinavir and darunavir. In the case of lopinavir, a decrease in van der Waals interactions is responsible for the lower binding affinity compared to alpha-ketoamide. On the other hand, in the case of darunavir, a decrease in the favorable intermolecular electrostatic and van der Waals interactions contributes to lower affinity compared to alpha-ketoamide. Our study might help in designing rational anti-coronaviral drugs targeting the SARS-CoV-2 main protease.","J Biomol Struct Dyn","Sk, Md Fulbabu","Roy, Rajarshi","Jonniya, Nisha Amarnath","Poddar, Sayan","Kar, Parimal","32396767"],"abstract":["The recent outbreak of novel \"coronavirus disease 2019\" (COVID-19) has spread rapidly worldwide, causing a global pandemic. In the present work, we have elucidated the mechanism of binding of two inhibitors, namely alpha-ketoamide and Z31792168, to SARS-CoV-2 main protease (M(pro) or 3CL(pro)) by using all-atom molecular dynamics simulations and free energy calculations. We calculated the total binding free energy (DeltaGbind) of both inhibitors and further decomposed DeltaGbind into various forces governing the complex formation using the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method. Our calculations reveal that alpha-ketoamide is more potent (DeltaGbind= - 9.05 kcal/mol) compared to Z31792168 (DeltaGbind= - 3.25 kcal/mol) against COVID-19 3CL(pro). The increase in DeltaGbind for alpha-ketoamide relative to Z31792168 arises due to an increase in the favorable electrostatic and van der Waals interactions between the inhibitor and 3CL(pro). Further, we have identified important residues controlling the 3CL(pro)-ligand binding from per-residue based decomposition of the binding free energy. Finally, we have compared DeltaGbind of these two inhibitors with the anti-HIV retroviral drugs, such as lopinavir and darunavir. It is observed that alpha-ketoamide is more potent compared to lopinavir and darunavir. In the case of lopinavir, a decrease in van der Waals interactions is responsible for the lower binding affinity compared to alpha-ketoamide. On the other hand, in the case of darunavir, a decrease in the favorable intermolecular electrostatic and van der Waals interactions contributes to lower affinity compared to alpha-ketoamide. Our study might help in designing rational anti-coronaviral drugs targeting the SARS-CoV-2 main protease."],"journal":"J Biomol Struct Dyn","authors":["Sk, Md Fulbabu","Roy, Rajarshi","Jonniya, Nisha Amarnath","Poddar, Sayan","Kar, Parimal"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396767","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/07391102.2020.1768149","keywords":["binding free energy","covid-19","mm-pbsa","molecular dynamics","sars-cov-2 3clpro"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827979517952,"score":296.3252}]}